AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Mortality rates for pneumonia caused by carbapenem-resistant A. baumannii (CRAB)—a Gram-negative pathogen—are above 50%, and more than half of A. baumannii infections are resistant to ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

When complications of pneumonia do develop in the pregnant patient ... Aminoglycosides should only be used if there is evidence of serious gram-negative infection, because the risk of ototoxicity ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

coli, Klebsiella pneumoniae, Pseudomonas aeruginosa ... are losing their ability to fight infections effectively.

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Methicillin-resistant Staphylococcus aureus (MRSA) is becoming an increasingly common pathogen in hospital-acquired pneumonia ... in some multidrug-resistant Gram-negative bacteria (e.g ...